Compare Novavax Inc (NVAX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs J M Smucker Co — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while J M Smucker Co trades at $112.69 (market cap $11.97B). The key difference: J M Smucker Co is far larger — about 9.2× Novavax Inc's market cap, and J M Smucker Co pays a 3.93% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SJM | |
|---|---|---|
Market Cap | $1.30B | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $117.05 |
52-Week Low | $6.22 | $89.53 |
Enterprise Value | $800.50M | $19.00B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
SJM trades at $115.75, up 3.34% today, showing strong momentum near resistance levels. The company maintains positive cash flow despite recent net losses, with operating cash flow of $1.21 billion in 2025. Recent dividend increases and analyst consensus support a bullish outlook, though profitability metrics remain challenged with negative ROE and net margins. Technical indicators show bullish momentum with the stock trading above key moving averages.
The investment case balances strong cash generation and dividend growth against profitability challenges. Analyst consensus targets $125.50 with 52% buy ratings, suggesting 8.4% upside potential. Key risks include persistent negative margins, high debt levels at 43.7% debt-to-asset ratio, and competitive pressures in the consumer staples sector. The company's Uncrustables division remains a key growth driver with nearly $1 billion in annual sales.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
